Population and methodology of the SIMETAP study: Prevalence of cardiovascular risk factors, cardiovascular diseases, and related metabolic diseases

Ruiz‐García, Antonio; Arranz-Martínez, Ezequiel; García-Álvarez, Juan Carlos; Morales-Cobos, Luis Enrique; García-Fernández, María Eugenia; Peña-Antón, Nuria de la; Calle, María Carmen Martín; Pérez, M. Cruz Díez; Costa, Alejandra Montero; Martinez, David; Villasur, M. Paloma García; Granado, Miriam; Borda, Maite; Herrainz, Juan Ángel Cique; Henrich, Nuria Marañón; Martín, Nieves Zarzuelo; Aller, Marcos; Calvo, Teresa; Álvaro, Pilar Arribas; Barrio, A.; Fernández, J.M. Ramos; Catalá, C. Ribot; Caldas, Mercedes Capitán; Pablo, Cristina Ciria de; Velasco, Carmelina Sanz; Stancampiano, Paula Simonaggio; Cabañero, Concepción Vargas-Machuca; Sanchez, Matilde; Díaz, Esther Gómez; Pozo, B. Sanz; Mingo, E. Rodríguez de; Igual, M; Perez, Marco; Valero, Alfonso Migueláñez; Bethencourt, Amelia Alcaraz; Urango, Concepción Zafra; Escuer, Paula Chao; Pedro, S. Redondo de; Guijarro, Nuria Escamilla; Uriarte, B. López; Teijido, Montserrat Rivera; Simetap, en nombre del Grupo de investigación del Estudio

doi:10.1016/j.artere.2018.08.001

Cited by 6 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the IBERICAN cohort, 48% of patients had hypertension. This frequency was higher than that reported in population-based surveys (30%–35%) ( 4 , 5 , 9 , 10 , 22 ). However, it should be noted that IBERICAN was a clinical-based study of patients seen in primary care setting.…”

Section: Discussioncontrasting

confidence: 70%

Clinical characteristics, treatment, and blood pressure control in patients with hypertension seen by primary care physicians in Spain: the IBERICAN study

Prieto-Díaz,

Pallares-Carratala,

Manuel Micó-Pérez

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

ObjectivesTo determine the clinical profile, according to the history of hypertension, the risk of developing hypertension, current antihypertensive treatment and BP control rates in patients with hypertension from the IBERICAN cohort.MethodsIBERICAN is an ongoing prospective cohort study, whose primary objective is to determine the frequency, incidence, and distribution of CVRF in the adult Spanish population seen in primary care settings. This analysis shows the baseline clinical characteristics of patients with hypertension. Adequate BP control was defined as BP <140/90 mmHg according to 2013 ESH/ESC guidelines.ResultsA total of 8,066 patients were consecutively included, of whom 3,860 (48.0%) had hypertension. These patients were older (65.8 ± 10.9 vs. 51.6 ± 14.7 years; p < 0.001), had more cardiovascular risk factors, target organ damage and cardiovascular disease (CVD) in comparison with those without hypertension. The risk of hypertension increased with the presence of associated CV risk factors and comorbidities, particularly diabetes, obesity and the metabolic syndrome, and decreased with the intensity of physical activity. Regarding antihypertensive treatments, 6.1% of patients did not take any medication, 38.8% were taking one antihypertensive drug, 35.5% two drugs, and 19.6% three or more antihypertensive drugs. Overall, 58.3% achieved BP goals <140/90 mmHg. A greater probability of BP control was observed with increasing age of patients and the greater number of antihypertensive drugs. Blood pressure control was lower in hypertensive patients with diabetes, obesity, the metabolic syndrome, increased urinary albumin excretion, higher pulse pressure, and lack of antihypertensive treatment.ConclusionsAbout half of patients attended in primary care settings have hypertension in Spain. Patients with hypertension have a worse CV clinical profile than non-hypertensive patients, with greater association of CVRF and CVD. Around four out of ten patients do not achieve the recommended BP goals, and higher use of combination therapies is associated with a better BP control.

show abstract

Section: Discussioncontrasting

confidence: 70%

Clinical characteristics, treatment, and blood pressure control in patients with hypertension seen by primary care physicians in Spain: the IBERICAN study

Prieto-Díaz,

Pallares-Carratala,

Manuel Micó-Pérez

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Los pacientes tratados con nilotinib tuvieron mayor probabilidad de presentar EAP y ECVA establecida que aquellos tratados con imatinib y dasatinib, lo que reafirma nuestro conocimiento sobre la capacidad de nilotinib para desarrollar ECVA y, especialmente, EAP. En España, el estudio observacional multicéntrico SIMETAP 37 , con más de 6.000 pacientes, determinó que el 9,20% de los sujetos presentaban ECVA (4,80% enfermedad coronaria, 3,80% ECV y 2,30% EAP). Con respecto al estudio de Coutinho Aunque en nuestro estudio la selección inicial del tratamiento con ITC está basada en los antecedentes personales, tanto hematológicos como cardiovasculares, con el fin de disminuir la probabilidad de efectos adversos a medio y largo plazo, no se encontraron diferencias estadísticamente significativas en cuanto a la prevalencia de FRCV en los grupos de tratamiento, salvo en la prevalencia de tabaquismo.…”

Section: Discussionunclassified

Prevalencia de los factores de riesgo cardiovascular, lesión de órgano diana y enfermedad cardiovascular subclínica y sintomática en una cohorte nacional de pacientes con leucemia mieloide crónica

Roa-Chamorro¹,

Puerta-Puerta²,

Torres-Quintero³

et al. 2022

SANGRE

View full text Add to dashboard Cite

Sin embargo, los ITC se han relacionado con un incremento en los eventos cardiovasculares que se producen fundamentalmente en pacientes que ya presentaban factores de riesgo cardiovascular (FRCV). Material y métodos: Estudio observacional, descriptivo y transversal de pacientes con LMC en tratamiento con ITC. Se estudió la prevalencia de FRCV, lesión de órgano diana y enfermedad cardiovascular aterosclerótica (ECVA) subclínica y sintomática.

show abstract

“…SIIMETAP-HF is a sub-study of the SIMETAP study [18], a multicenter cross-sectional observational study, authorized by the Health Service of the Community of Madrid (SER-MAS according to its initials in Spanish), which 121 physicians participated in. The physicians were selected competitively to reach the necessary sample size and belonged to 64 primary care centers (25.6% from de SERMAS healthcare centers).…”

Section: Methodsmentioning

confidence: 99%

Heart Failure Prevalence Rates and Its Association with Other Cardiovascular Diseases and Chronic Kidney Disease: SIMETAP-HF Study

Ruiz-García

Serrano-Cumplido

Cervantes

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

Introduction and objectives: Heart failure (HF) is a major health problem that causes high mortality and hospitalization rates. This study aims to determine the HF prevalence rates in populations aged both ≥18 years and ≥50 years and to assess its association with cardiovascular diseases and chronic kidney disease. Methods: A cross-sectional observational study was conducted in a primary care setting, with a population-based random sample of 6588 people aged 18.0–102.8 years. Crude and adjusted prevalence rates of HF were calculated. The associations of renal and cardiometabolic factors with HF were assessed in both populations using univariate, bivariate and multivariate analysis. Results: The HF crude prevalence rates were 2.8% (95%CI: 2.4–3.2) in adults (≥18 years), and 4.6% (95%CI: 4.0–5.3) in the population aged ≥ 50 years, without significant differences between males and females in both populations. The age- and sex-adjusted prevalence rates were 2.1% (male: 1.9%; female: 2.3%) in the overall adult population, and 4.5% (male: 4.2%; female: 4.8%) in the population aged ≥ 50 years, reaching 10.0% in the population aged ≥ 70 years. Atrial fibrillation, hypertension, low estimated glomerular filtration rate (eGFR), coronary heart disease (CHD), stroke, sedentary lifestyle, and diabetes were independently associated with HF in both populations. A total of 95.7% (95%CI: 92.7–98.6) of the population with HF had an elevated cardiovascular risk. Conclusions: This study reports that HF prevalence increases from 4.5% in the population over 50 years to 10% in the population over 70 years. The main clinical conditions that are HF-related are sedentary lifestyle, atrial fibrillation, hypertension, diabetes, low eGFR, stroke, and CHD.

show abstract

Population and methodology of the SIMETAP study: Prevalence of cardiovascular risk factors, cardiovascular diseases, and related metabolic diseases

Cited by 6 publications

References 31 publications

Clinical characteristics, treatment, and blood pressure control in patients with hypertension seen by primary care physicians in Spain: the IBERICAN study

Clinical characteristics, treatment, and blood pressure control in patients with hypertension seen by primary care physicians in Spain: the IBERICAN study

Prevalencia de los factores de riesgo cardiovascular, lesión de órgano diana y enfermedad cardiovascular subclínica y sintomática en una cohorte nacional de pacientes con leucemia mieloide crónica

Heart Failure Prevalence Rates and Its Association with Other Cardiovascular Diseases and Chronic Kidney Disease: SIMETAP-HF Study

Contact Info

Product

Resources

About